Download PDF
Semin Respir Crit Care Med 2000; 21(4): 349-356
DOI: 10.1055/s-2000-9859
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Clinical Spectrum of Stenotrophomonas (Xanthomonas) Maltophilia Respiratory Infection

Shahe E. Vartivarian, Elias J. Anaissie, Elias N. Kiwan, Konstantinos A. Papadakis
  • Presented in part at the 34th Annual Meeting of the Infectious Disease Society of America (IDSA), September 1996, New Orleans, LA. Supported in part by a grant from Merck, Sharp, & Dohme. Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas (E.J.A, and E.N.K.); Metropolitan Infectious Disease Associates, Houston, Texas (S.E.V); and The University of Texas Medical School, Houston, Texas (K.A.P)
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

During a 15-month retrospective clinical study in an academic referral-based cancer center, 26 patients with S. maltophilia respiratory tract infections were identified (which were associated with bacteremia in 13 patients). Five of these 26 patients had previously undescribed sinopulmonary involvement. The infections were typically nosocomial. Nine patients with solid tumors had malignant involvement of the respiratory tract (five with obstruction). In two patients, the infection co-existed with pulmonary aspergillosis. Fifteen patients (58%) died of the infection. The factors that correlated with a poor outcome included bacteremic pneumonia, persistent neutropenia, presence of obstruction, development of septic shock or multiple organ dysfunction, and delay in institution of appropriate antibiotic therapy. In multivariate analysis, only septic shock and delayed therapy remained significant. Trimethoprim-sulfamethoxazole and/or ticarcillin-clavulanate were most commonly associated with a favorable outcome.

KEYWORD

Stenotrophomonas maltophilia, Multidrug-resistance - trimethoprim-sulfamethoxazole

REFERENCES

  • 1 Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: Implications for therapy.  Antimicrob Agents Chemother . 1994;  38 624-627
    PubMedGoogle Scholar
  • 2 Marshall W F, Keating M R, Anhalt J P, Steckelberg J M. Xanthomonas maltophilia: An emerging nosocomial pathogen.  Mayo Clin Proc . 1989;  64 1097-1104
    PubMedGoogle Scholar
  • 3 Vartivarian S E, Papadakis K A, Palacios J A, Manning Jr T J, Anaissie E J. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.  Ann Intern Med . 1994;  121 969-973
    PubMedGoogle Scholar
  • 4 Papadakis K A, Vartivarian S E, Vassilaki M E, Anaissie E J. Stenotrophomonas maltophilia: An unusual cause of biliary sepsis.  Clin Infect Dis . 1995;  21 1032-1034
    PubMedGoogle Scholar
  • 5 Vartivarian S E, Papadakis K A, Anaissie E J. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated.  Arch Intern Med . 1996;  156 433-435
    CrossrefPubMedGoogle Scholar
  • 6 VanCouwenberghe C J, Farver T B, Cohen S H. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens.  Infect Control Hosp Epidemiol . 1997;  18 316-321
    PubMedGoogle Scholar
  • 7 Gopalakrishnan R, Hawley H B, Czachor J S, Markert R J, Bernstein J M. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: A study of 143 patients.  Heart Lung . 1999;  28 134-141
    CrossrefPubMedGoogle Scholar
  • 8 Vartivarian S E, Anaissie E J. Stenotrophomonas maltophilia and Burkholderia cepacia In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Vol. 2. Philadelphia: Churchill Livingstone;2000;2335- 2339
    Google Scholar
  • 9 Demko C A, Stern R C, Doershuk C F. Stenotrophomonas maltophilia in cystic fibrosis: Incidence and prevalence.  Pediatr Pulmonol . 1998;  25 304-308
    CrossrefPubMedGoogle Scholar
  • 10 Franzetti F, Cernuschi M, Esposito R, Moroni M. Pseudomonas infections in patients with AIDS and AIDS-related complex.  J Intern Med . 1992;  231 437-443
    PubMedGoogle Scholar
  • 11 Sarkar T K, Gilardi G, Aguam A S, Josephson J, Leventhal G L. Primary Pseudomonas maltophilia infection of the lung.  Postgrad Med. 1979;  65 253-256 260
    PubMedGoogle Scholar
  • 12 Liaw Y S, Yang P C, Wu Z G. The bacteriology of obstructive pneumonitis. A prospective study using ultrasound-guided transthoracic needle aspiration.  Am J Respir Crit Care Med . 1994;  149 1648-1653
    PubMedGoogle Scholar
  • 13 Spencer R C. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia.  J Hosp Infect . 1995;  30 453-464
    CrossrefPubMedGoogle Scholar
  • 14 Bone R C. Gram-positive organisms and sepsis.  Arch Intern Med . 1994;  154 26-34
    CrossrefPubMedGoogle Scholar
  • 15 Zuravleff J J, Yu V L. Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: Case reports and a review of the literature.  Rev Infect Dis . 1982;  4 1236-1246
    PubMedGoogle Scholar
  • 16 Gardner P, Griffin W B, Swartz M N, Kunz L J. Nonfermentative gram-negative bacilli of nosocomial interest.  Am J Med . 1970;  48 735-749
    PubMedGoogle Scholar
  • 17 Pennington J E, Reynolds H Y, Carbone P P. Pseudomonas pneumonia. A retrospective study of 36 cases.  Am J Med . 1973;  55 155-160
    CrossrefPubMedGoogle Scholar
  • 18 Phair J P, Bassaris H P, Williams J E, Metzger E. Bacteremic pneumonia due to gram-negative bacilli.  Arch Intern Med . 1983;  143 2147-2149
    CrossrefPubMedGoogle Scholar
  • 19 Karnad A, Alvarez S, Berk S L. Pneumonia caused by gram-negative bacilli.  Am J Med . 1985;  79 61-67
    CrossrefPubMedGoogle Scholar
  • 20 Rose H D, Heckman M G, Unger J D. Pseudomonas aeruginosa pneumonia in adults.  Am Rev Respir Dis . 1973;  107 416-422
    PubMedGoogle Scholar
  • 21 Jonas M, Cunha B A. Bacteremic Escherichia coli pneumonia.  Arch Intern Med . 1982;  142 2157-2159
    CrossrefPubMedGoogle Scholar
  • 22 Niederman M S. Gram-negative colonization of the respiratory tract: Pathogenesis and clinical consequences.  Semin Respir Infect . 1990;  5 173-184
    PubMedGoogle Scholar
  • 23 Davin-Regli A, Bollet C, Auffray J P, Saux P, De Micco P. Use of random amplified polymorphic DNA for epidemiological typing of Stenotrophomonas maltophilia.  J Hosp Infect . 1996;  32 39-50
    CrossrefPubMedGoogle Scholar
  • 24 Vartivarian S E, Papadakis K, Anaissie E J. Outcome of Stenotrophomonas maltophilia infection sin cancer patients. In: Interscience Conference on Antrimicrobial agents and Chemotherapy; 1997 Sept 28-Oct 1, Toronto, Ontario, Canada
    Google Scholar
  • 25 Villarino M E, Stevens L E, Schable B. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients.  Infect Control Hosp Epidemiol . 1992;  13 201-206
    PubMedGoogle Scholar
  • 26 Nagai T. Association of Pseudomonas maltophilia with malignant lesions.  J Clin Microbiol . 1984;  20 1003-1005
    PubMedGoogle Scholar
  • 27 Hutchinson G R, Parker S, Pryor J A. Home-use nebulizers: A potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis [published erratum appears in J Clin Microbiol 1996;34(6):1601].  J Clini Microbiol . 1996;  34 584-587
    PubMedGoogle Scholar
  • 28 Vartivarian S E, Papadakis K A, Palacios J A, Manning Jr T J, Anaissie E J. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.  Ann Intern Med . 1994;  121 969-973
    PubMedGoogle Scholar
  • 29 Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: Implications for therapy.  Antimicrob Agents Chemother . 1994;  38 624-627
    PubMedGoogle Scholar
      >